Dinoprost
Based on 10 publication(s) in Google Scholar
Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.84%
- No. CAS: 551-11-1
- Fòrmula: C20H34O5
- Peso molecular:354.48
-
Almacenamiento:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-101952
Prostaglandin E2Prostaglandin Receptor Agonist -
HY-101988
Prostaglandin D2Prostaglandin -
HY-B0131
Prostaglandin E1Vasodilator -
HY-109590
Arachidonic acidPolyunsaturated Fatty Acid -
HY-B0577
LatanoprostProstaglandin Receptor Agonist -
HY-18739
Phorbol 12-myristate 13-acetatePKC Activator -
HY-B2167
Docosahexaenoic acidomega-3 Fatty Acid -
HY-13948
Angiotensin II humanVasoconstrictor -
HY-101952R
Prostaglandin E2 (Standard) -
HY-101952G
Prostaglandin E2 (GMP)Inflammatory Mediator (GMP) -
HY-B0660
Eicosapentaenoic AcidLC-PUFA -
HY-I0960
UracilPyrimidine Derivative
Publications Citing Use of MedChemExpress (MCE) Dinoprost
More- Cell Metab. 2026 Jan 9:S1550-4131(25)00546-7. [Abstract]
- Nat Commun. 2023 May 9;14(1):2668. [Abstract]
- Phytomedicine. 2025 Jul 25:143:156866. [Abstract]
- Int J Mol Sci. 2023 Apr 10;24(8):7012. [Abstract]
- ACS Pharmacol Transl Sci. 2025 Oct 4;8(11):4095-4106. [Abstract]
- Pathol Res Pract. 2026 Jun:282:156467. [Abstract]
- Fitoterapia. 2026 Mar 17.
- Patent. US20260001892A1.
- Patent. US20250250283A1.
- Patent. US20250154162A1.
Customer Validation & Images
-
Histological Imaging/Staining
-
WB
-
RT-PCR
-
Cell Imaging/Staining
-
WB
Ver todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
Descripciòn
|
FP Receptor |
Human Endogenous Metabolite |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
>10000 nM
Compound: PGF2
|
Affinity for Prostanoid EP2 receptor expressed in CHO cells
Affinity for Prostanoid EP2 receptor expressed in CHO cells
|
[PMID: 10715159] |
| CHO | IC50 |
>10000 nM
Compound: PGF2
|
Affinity for Prostanoid TP receptor expressed in CHO cells
Affinity for Prostanoid TP receptor expressed in CHO cells
|
[PMID: 10715159] |
| CHO | IC50 |
322 nM
Compound: PGF2
|
Affinity for Prostanoid EP3 receptor expressed in CHO cell line
Affinity for Prostanoid EP3 receptor expressed in CHO cell line
|
[PMID: 10715159] |
| CHO | IC50 |
4200 nM
Compound: PGF2
|
Affinity for Prostanoid EP4 receptor expressed in CHO cells
Affinity for Prostanoid EP4 receptor expressed in CHO cells
|
[PMID: 10715159] |
| CHO | IC50 |
>10000 nM
Compound: PGF2
|
Affinity for Prostaglandin I2 receptor expressed in CHO cells
Affinity for Prostaglandin I2 receptor expressed in CHO cells
|
[PMID: 10715159] |
| COS-7 | IC50 |
380 nM
Compound: PGF2
|
Affinity for Prostanoid EP1 receptor expressed in COS-7 cells.
Affinity for Prostanoid EP1 receptor expressed in COS-7 cells.
|
[PMID: 10715159] |
| COS-7 | IC50 |
7 nM
Compound: PGF2
|
Affinity for human Prostanoid FP receptor expressed in COS-7 cells
Affinity for human Prostanoid FP receptor expressed in COS-7 cells
|
[PMID: 10715159] |
| HEK293 | IC50 |
4500 nM
Compound: PGF2
|
Affinity for human Prostaglandin D2 receptor expressed in HEK293 cells
Affinity for human Prostaglandin D2 receptor expressed in HEK293 cells
|
[PMID: 10715159] |
| K562 | IC50 |
>700 μM
Compound: 1
|
In vitro antiproliferative activity was measured on human leukemia K562 cells
In vitro antiproliferative activity was measured on human leukemia K562 cells
|
10.1016/S0960-894X(00)80372-8 |
| NIH3T3 | EC50 |
24.5 nM
Compound: PGF2 alpha
|
Efficacy for stimulation of prostanoid FP receptor-linked phosphoinositide turnover in Swiss 3T3 mouse fibroblast cells
Efficacy for stimulation of prostanoid FP receptor-linked phosphoinositide turnover in Swiss 3T3 mouse fibroblast cells
|
[PMID: 15357985] |
| NIH3T3 | EC50 |
24.5 nM
Compound: PGF2alpha
|
Agonist activity at FP receptor in Swiss mouse 3T3 cells assessed as [3H]-IP accumulation by scintillation counting
Agonist activity at FP receptor in Swiss mouse 3T3 cells assessed as [3H]-IP accumulation by scintillation counting
|
[PMID: 19101156] |
| Oocyte | IC50 |
0.287 μM
Compound: Prostaglandin F2alpha
|
TP_TRANSPORTER: inhibition of PGD2 uptake in Xenopus laevis oocytes
TP_TRANSPORTER: inhibition of PGD2 uptake in Xenopus laevis oocytes
|
[PMID: 10973807] |
In Vitro
Dinoprost (Prostaglandin F2α; 1 μM; for 24 hours) induces ER stress, autophagy, and apoptosis in goat luteal cells[1].
Dinoprost (1 μM; for 24 hours) significantly increases the expression of GRP78 and UPR sensors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Goat luteal cells
-
Concentration:1 μM
-
Incubation Time:For 24 hours
-
Result:Significantly increased the apoptotic rate (15.62±3.12%).
-
Cell Line:Goat luteal cells
-
Concentration:1 μM
-
Incubation Time:For 24 hours
-
Result:There was extensive overlap between LC3 and LAMP1 in luteal cells and autophagolysosomes were formed in goat luteal cells.
-
Cell Line:Goat luteal cells
-
Concentration:1 μM
-
Incubation Time:For 24 hours
-
Result:The expression of GRP78 and UPR sensors including cleaved ATF6, phosphorylated-EIF2S1, EIF2S1, ATF4, phosphorylated-IRE1, autophagy-related protein LC3-II, and pro-apoptosis factor cleaved Caspase3 increased significantly in the cells.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 551-11-1
-
Appearance <25°C Solid,>35°C Liquid
-
Peso molecular 354.48
-
Fòrmula C20H34O5
-
Color White to light brown
-
SMILES
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(O)=O
-
Synonyms
Prostaglandin F2α; PGF2α
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
2026 Jan 9:S1550-4131(25)00546-7. PMID: 41519131 -
Nat Commun
2023 May 9;14(1):2668. PMID: 37160891 -
Phytomedicine
Evodiamine inhibits NLRP3 inflammasome-mediated microglial pyroptosis and promotes remyelination via SLC2A4-regulated autophagy. [Abstract]2025 Jul 25:143:156866. PMID: 40393245
Dinoprost purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jul 25:143:156866. [Abstract]
Dinoprost (20 mg/kg/d for 10 days, intraperitoneally injected). Representative images of MBP and LFB staining (scale bar, 500 μm) (n = 6), and transmission electron microscopy (scale bar, 1 μm) (n = 6) in the corpus callosum region of different groups of mice.
Dinoprost purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jul 25:143:156866. [Abstract]
Dinoprost (20 mg/kg/d for 10 days, intraperitoneally injected). Expression of SLC2A4 and MBP in the mouse corpus callosum determined and statistically analyzed by protein immunoblotting.
Dinoprost purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jul 25:143:156866. [Abstract]
Dinoprost (20 mg/kg/d for 10 days, intraperitoneally injected). Expression of SLC2A4 and MBP in the mouse corpus callosum determined and statistically analyzed by real-time PCR.
Dinoprost purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jul 25:143:156866. [Abstract]
LPS+ATP-induced pyroptosis treated with EVO (at different concentrations) and SLC2A4 inhibitor Dinoprost (PGF2α, 1 μM, 24 h) followed by eGFP-mCherry probe detection of autophagic flux (scale bar, 20 μm) and fluorescence detection of SLC2A4 (scale bar, 50 μm): LAMP1 (green), LC3B (red), and DAPI (blue) (scale bar, 50 μm).
Dinoprost purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jul 25:143:156866. [Abstract]
Western blot analysis of pyroptotic proteins GSDMD, GSDMD-N, and NLRP3 inflammasome expression after LPS+ATP induced-pyroptosis, and EVO and SLC2A4 inhibitor Dinoprost (PGF2α, 1 μM, 24 h) treatment.
Dinoprost purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jul 25:143:156866. [Abstract]
Expressions of autophagy-related proteins P62, Beclin1, and LC3B detected by western blot after LPS+ATP induced-pyroptosis, and EVO and SLC2A4 inhibitor PGF2α treatment.
-
Int J Mol Sci
Prostaglandin F2α Regulates Adipogenesis by Modulating Extracellular Signal-Regulated Kinase Signaling in Graves' Ophthalmopathy. [Abstract]2023 Apr 10;24(8):7012. PMID: 37108173 -
ACS Pharmacol Transl Sci
Ultrasensitive Profiling of Arachidonic Acid Metabolites Based on 5‑(Diisopropylamino)amylamine Derivatization-Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry. [Abstract]2025 Oct 4;8(11):4095-4106. PMID: 41262585 -
Pathol Res Pract
Prostaglandin F2α impairs skin regeneration via FP receptor-mediated oxidative stress overriding autophagic protection in fibroblasts. [Abstract]2026 Jun:282:156467. PMID: 41985369 -
-
-
-
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (282.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Hagen Thieme, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45. [Content Brief]
[2]. Xin Wen, et al. Prostaglandin F2α Induces Goat Corpus Luteum Regression via Endoplasmic Reticulum Stress and Autophagy. Front Physiol. 2020 Sep 11;11:868. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8210 mL | 14.1052 mL | 28.2103 mL | 70.5258 mL |
| 5 mM | 0.5642 mL | 2.8210 mL | 5.6421 mL | 14.1052 mL | |
| 10 mM | 0.2821 mL | 1.4105 mL | 2.8210 mL | 7.0526 mL | |
| 15 mM | 0.1881 mL | 0.9403 mL | 1.8807 mL | 4.7017 mL | |
| 20 mM | 0.1411 mL | 0.7053 mL | 1.4105 mL | 3.5263 mL | |
| 25 mM | 0.1128 mL | 0.5642 mL | 1.1284 mL | 2.8210 mL | |
| 30 mM | 0.0940 mL | 0.4702 mL | 0.9403 mL | 2.3509 mL | |
| 40 mM | 0.0705 mL | 0.3526 mL | 0.7053 mL | 1.7631 mL | |
| 50 mM | 0.0564 mL | 0.2821 mL | 0.5642 mL | 1.4105 mL | |
| 60 mM | 0.0470 mL | 0.2351 mL | 0.4702 mL | 1.1754 mL | |
| 80 mM | 0.0353 mL | 0.1763 mL | 0.3526 mL | 0.8816 mL | |
| 100 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7053 mL |
Dinoprost Related Classifications
HY-12956 Related Classifications
Powered by Bioz